Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $101.5 million versus the consensus estimate of $111.2 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.